139 related articles for article (PubMed ID: 34463378)
1. Cardiopulmonary exercise testing has greater prognostic value than sarcopenia in oesophago-gastric cancer patients undergoing neoadjuvant therapy and surgical resection.
West MA; Baker WC; Rahman S; Munro A; Jack S; Grocott MP; Underwood TJ; Levett DZ;
J Surg Oncol; 2021 Dec; 124(8):1306-1316. PubMed ID: 34463378
[TBL] [Abstract][Full Text] [Related]
2. Myosteatosis is associated with poor physical fitness in patients undergoing hepatopancreatobiliary surgery.
West MA; van Dijk DPJ; Gleadowe F; Reeves T; Primrose JN; Abu Hilal M; Edwards MR; Jack S; Rensen SSS; Grocott MPW; Levett DZH; Olde Damink SWM
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):860-871. PubMed ID: 31115169
[TBL] [Abstract][Full Text] [Related]
3. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
4. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
[TBL] [Abstract][Full Text] [Related]
5. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
6. Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer.
Navidi M; Phillips AW; Griffin SM; Duffield KE; Greystoke A; Sumpter K; Sinclair RCF
Br J Surg; 2018 Jun; 105(7):900-906. PubMed ID: 29601082
[TBL] [Abstract][Full Text] [Related]
7. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.
den Boer RB; Jones KI; Ash S; van Boxel GI; Gillies RS; O'Donnell T; Ruurda JP; Sgromo B; Silva MA; Maynard ND
BJS Open; 2020 Oct; 4(5):847-854. PubMed ID: 32841538
[TBL] [Abstract][Full Text] [Related]
8. Routine pre- and post-neoadjuvant chemotherapy fitness testing is not indicated for oesophagogastric cancer surgery.
Drummond RJ; Vass D; Wadhawan H; Craig CF; MacKay CK; Fullarton GM; Forshaw MJ
Ann R Coll Surg Engl; 2018 Sep; 100(7):515-519. PubMed ID: 29692190
[TBL] [Abstract][Full Text] [Related]
9. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Computed Tomography (CT)-Defined Muscle and Adipose Tissue Features in Relation to Short-Term Outcomes After Elective Surgery for Colorectal Cancer: A Multicenter Approach.
Martin L; Hopkins J; Malietzis G; Jenkins JT; Sawyer MB; Brisebois R; MacLean A; Nelson G; Gramlich L; Baracos VE
Ann Surg Oncol; 2018 Sep; 25(9):2669-2680. PubMed ID: 30006691
[TBL] [Abstract][Full Text] [Related]
11. Patient's Skeletal Muscle Radiation Attenuation and Sarcopenic Obesity are Associated with Postoperative Morbidity after Neoadjuvant Chemoradiation and Resection for Rectal Cancer.
Berkel AEM; Klaase JM; de Graaff F; Brusse-Keizer MGJ; Bongers BC; van Meeteren NLU
Dig Surg; 2019; 36(5):376-383. PubMed ID: 29898443
[TBL] [Abstract][Full Text] [Related]
12. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of skeletal muscle mass change during the neoadjuvant chemotherapy period in patients with gastric cancer: An ancillary study of JCOG1002.
Sato R; Tokunaga M; Mizusawa J; Sato Y; Ito S; Takahari D; Sano T; Onaya H; Yoshikawa T; Boku N; Terashima M
World J Surg; 2024 Jan; 48(1):163-174. PubMed ID: 38686798
[TBL] [Abstract][Full Text] [Related]
14. Skeletal muscle wasting during neoadjuvant therapy as a prognosticator in patients with esophageal and esophagogastric junction cancer: A systematic review and meta-analysis.
Wang P; Wang S; Li X; Lin G; Ma Y; Xiao R; Li H; Qiu M; Yang F
Int J Surg; 2022 Jan; 97():106206. PubMed ID: 34990833
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?
Saeki H; Nakashima Y; Kudou K; Sasaki S; Jogo T; Hirose K; Edahiro K; Korehisa S; Taniguchi D; Nakanishi R; Kubo N; Ando K; Kabashima A; Oki E; Maehara Y
World J Surg; 2018 Sep; 42(9):2894-2901. PubMed ID: 29488065
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of skeletal muscle measurement by computed tomography in patients with esophageal cancer: changes in skeletal muscle mass due to neoadjuvant therapy and the effect on the prognosis.
Yamamoto M; Ozawa S; Koyanagi K; Kazuno A; Ninomiya Y; Yatabe K; Higuchi T; Kanamori K; Tajima K
Surg Today; 2023 Jun; 53(6):692-701. PubMed ID: 36763134
[TBL] [Abstract][Full Text] [Related]
17. Multimodal Prehabilitation During Neoadjuvant Therapy Prior to Esophagogastric Cancer Resection: Effect on Cardiopulmonary Exercise Test Performance, Muscle Mass and Quality of Life-A Pilot Randomized Clinical Trial.
Allen SK; Brown V; White D; King D; Hunt J; Wainwright J; Emery A; Hodge E; Kehinde A; Prabhu P; Rockall TA; Preston SR; Sultan J
Ann Surg Oncol; 2022 Mar; 29(3):1839-1850. PubMed ID: 34725764
[TBL] [Abstract][Full Text] [Related]
18. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
[TBL] [Abstract][Full Text] [Related]
19. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
20. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
